爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

sandoz pharmaceuticals d.d. - klosapiin - tablett - 50mg 84tk; 50mg 50tk; 50mg 30tk; 50mg 40tk; 50mg 5000tk; 50mg 500tk; 50mg 100tk; 50mg 28tk; 50mg 20tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

sandoz pharmaceuticals d.d. - klosapiin - tablett - 100mg 5000tk; 100mg 84tk; 100mg 98tk; 100mg 20tk; 100mg 30tk; 100mg 28tk; 100mg 50tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

sandoz pharmaceuticals d.d. - klosapiin - tablett - 25mg 100tk; 25mg 84tk; 25mg 30tk; 25mg 98tk; 25mg 500tk; 25mg 250tk; 25mg 20tk; 25mg 28tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

gedeon richter plc. - haloperidool - süstelahus - 5mg 1ml 1ml 5tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

gedeon richter plc. - haloperidool - süstelahus - 50mg 1ml 1ml 5tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - asatsitidiin - leukeemia, müeloidne, äge - antineoplastilised ained - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mitu müeloomit - antineoplastilised ained - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastilised ained - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris on näidustatud ravi täiskasvanud patsientidel, kellel on taastekkinud või tulekindlad cd30+ hodgkini lümfoom (hl):pärast asct, orfollowing vähemalt kaks enne ravi kui asct või multi-agent keemiaravi ei ole ravi valik. süsteemne anaplastic suur kärje lymphomaadcetris koos tsüklofosfamiidi, doxorubicin ja prednisoon (chp) on näidustatud täiskasvanud patsientidel, kellel on varem ravimata süsteemne anaplastic suur raku lümfoom (salcl). adcetris on näidustatud ravi täiskasvanud patsientidel, kellel on taastekkinud või tulekindlad salcl. naha t-rakkude lymphomaadcetris on näidustatud ravi täiskasvanud patsientidel, kellel cd30+ naha t-raku lümfoom (ctcl) pärast vähemalt 1 enne süsteemset ravi.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

sanofi b.v. - eliglustat - gaucheri tõbi - muud alimentary seedetrakti ja ainevahetust tooted, - cerdelga on näidustatud pikaajaliseks raviks täiskasvanud patsientidel gaucher haiguse tüüp 1 (gd1), kes on cyp2d6 metaboliseerijatel (pms), annuses (ims) või kõrge (ems).